| Kristen Michelle Clow, MA, LCPC | |
|
3233 Mathers Road Suite A, 62711, IL 62704 | |
| (217) 414-2064 | |
| Not Available |
| Full Name | Kristen Michelle Clow |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 3233 Mathers Road Suite A, 62711, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770221426 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Michelle Clow, MA, LCPC 1221 W Pine St, Springfield, IL 62704-3548 Ph: (217) 416-0737 | Kristen Michelle Clow, MA, LCPC 3233 Mathers Road Suite A, 62711, IL 62704 Ph: (217) 414-2064 |
News Archive
Beckman Coulter Life Sciences re-emerges as an innovator in automated liquid handling solutions with today's introduction of the Biomek i-Series Automated Workstations, at the 2017 international conference of the Society for Laboratory Automation and Screening in Washington D.C.
Bionumbers, LLC announced top-line figures from the second report in its Parameters of Performance series: "DD09 - Drug Delivery Product Success Rates, Development Times, Costs and Marketing Exclusivity."
A new review of studies refutes earlier knowledge and says salt may not be as bad for the heart as commonly believed. Researchers from the Universities of Exeter and Plymouth in Exeter, U.K. reviewed data for the Cochrane Library from seven studies with nearly 6,500 participants who reduced their salt intake and found that while eating less salt did lower blood pressure, it did not reduce the risk of dying or of having heart disease.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
› Verified 5 days ago